TYRP1 and melanoma: Currently, an active clinical trial (NCT03865212) is evaluating a recombinant vesicular stomatitis virus (VSV) platform expressing IFNβ and tyrosinase-related protein 1 (TYRP1), a melanoma-specific antigen.